Tango Therapeutics, Inc.

NasdaqGM:TNGX Rapport sur les actions

Capitalisation boursière : US$4.3b

Tango Therapeutics Gestion

Gestion contrôle des critères 2/4

Le PDG Tango Therapeutics est Malte Peters, nommé en Jan2026, a un mandat de moins d'un an. détient directement 0.008% des actions de la société, d'une valeur de $ 335.58K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 0.4 ans et 5.3 ans.

Informations clés

Malte Peters

Directeur général

US$1.2m

Rémunération totale

Pourcentage du salaire du PDGn/a
Durée du mandat du directeur généralless than a year
Propriété du PDG0.008%
Durée moyenne d'occupation des postes de directionless than a year
Durée moyenne du mandat des membres du conseil d'administration5.3yrs

Mises à jour récentes de la gestion

Recent updates

Seeking Alpha • Jun 09

Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite

Summary Tango Therapeutics, Inc. surged over 625% since January 2025, driven by best-in-class Phase 1/2 data for vopimetostat in combination with RAS inhibitors. Vopimetostat plus daraxonrasib achieved a 92% objective response rate in MTAP-deleted, RAS-mutant metastatic pancreatic cancer, supporting rapid advancement to Phase 3. TNGX is now exclusively focused on PRMT5 inhibitors, with robust funding—$380M cash plus a $500M equity raise—supporting operations into 2028. I maintain a Hold rating for TNGX, citing the need for clarity on Tango’s and Revolution’s strategic paths, upcoming monotherapy data, and potential M&A interest. Read the full article on Seeking Alpha
Article d’analyse • Jan 19

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 53% Price Boost Is Out Of Tune With Revenues

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders have had their patience rewarded with a 53% share price jump in...
Article d’analyse • Dec 05

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 32%

Despite an already strong run, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have been powering on, with a gain of...
Article d’analyse • Sep 17

Tango Therapeutics, Inc. (NASDAQ:TNGX) Investors Are Less Pessimistic Than Expected

With a price-to-sales (or "P/S") ratio of 33.7x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be sending very bearish...
Article d’analyse • May 15

US$10.43: That's What Analysts Think Tango Therapeutics, Inc. (NASDAQ:TNGX) Is Worth After Its Latest Results

The analysts might have been a bit too bullish on Tango Therapeutics, Inc. ( NASDAQ:TNGX ), given that the company fell...
Article d’analyse • Apr 14

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 28% in the last...
Article d’analyse • Apr 04

Here's Why We're Watching Tango Therapeutics' (NASDAQ:TNGX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d’analyse • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Article d’analyse • Feb 28

Tango Therapeutics, Inc. (NASDAQ:TNGX) Not Doing Enough For Some Investors As Its Shares Slump 30%

To the annoyance of some shareholders, Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares are down a considerable 30% in...
Seeking Alpha • Jan 23

Tango Therapeutics: Chance For A Short Squeeze

Summary Tango Therapeutics is a growing cancer drug development company with partners such as Gilead Sciences. Given the high short interest and the low number of shares outstanding, I expect a short squeeze to occur, which could lead to an increase in TNGX's share price thereafter. Despite the negative sentiment, recent institutional selling and call option activity suggest potential value accumulation and positive momentum for TNGX. I decided to buy OTM call options on TNGX due to the low implied volatility. Read the full article on Seeking Alpha
Article d’analyse • Dec 05

Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d’analyse • Oct 31

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Unfortunately for some shareholders, the Tango Therapeutics, Inc. ( NASDAQ:TNGX ) share price has dived 26% in the last...
Seeking Alpha • Sep 10

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Summary Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts. Despite the high risk, Tango's differentiated approach and potential blockbuster candidates make TNGX stock an intriguing speculative buy ahead of critical data readouts. Read the full article on Seeking Alpha
Article d’analyse • Sep 01

What Tango Therapeutics, Inc.'s (NASDAQ:TNGX) 29% Share Price Gain Is Not Telling You

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have continued their recent momentum with a 29% gain in the last month...
Article d’analyse • Jun 29

Subdued Growth No Barrier To Tango Therapeutics, Inc. (NASDAQ:TNGX) With Shares Advancing 27%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a really impressive month, gaining 27% after a shaky period...
Article d’analyse • May 30

Shareholders May Not Be So Generous With Tango Therapeutics, Inc.'s (NASDAQ:TNGX) CEO Compensation And Here's Why

Key Insights Tango Therapeutics will host its Annual General Meeting on 5th of June Salary of US$626.0k is part of CEO...
Article d’analyse • Mar 19

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shares have had a horrible month, losing 30% after a relatively good period...
Article d’analyse • Mar 06

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Tango Therapeutics...
Article d’analyse • Jan 08

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

You may think that with a price-to-sales (or "P/S") ratio of 25x Tango Therapeutics, Inc. ( NASDAQ:TNGX ) is a stock to...
Article d’analyse • Nov 09

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Shareholders in Tango Therapeutics, Inc. ( NASDAQ:TNGX ) may be thrilled to learn that the analysts have just delivered...
Article d’analyse • Aug 12

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Tango Therapeutics, Inc. ( NASDAQ:TNGX ) shareholders will have a reason to smile today, with the analysts making...
Article d’analyse • May 10

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 20

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

H.C. Wainwright has started Tango Therapeutics (NASDAQ:TNGX) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets the company is focused on could potentially treat large patient populations. He cited TNG908, Tango's (TNGX) most advanced candidate, currently in phase 1/2 for MTAP-deleted tumors. Initial data is expected in H1 2023. After determining the optimum dose for TNG908, Tango (TNGX) says it will evaluate efficacy in multiple tumor types in specific cohorts, including malignant peripheral nerve sheath tumor, non-small cell lung cancer, mesothelioma, cholangiocarcinoma, and glioblastoma. Seeking Alpha's Quant Rating views Tango (TNGX) as a buy with high marks for growth and momentum.
Article d’analyse • Oct 05

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Article d’analyse • Aug 13

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

The investors in Tango Therapeutics, Inc. 's ( NASDAQ:TNGX ) will be rubbing their hands together with glee today...
Seeking Alpha • Aug 10

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Tango Therapeutics press release (NASDAQ:TNGX): Q2 GAAP EPS of -$0.28 beats by $0.03. Revenue of $5.78M (-68.2% Y/Y) beats by $0.12M.

PDG

Malte Peters (64 yo)

less than a year
Titularisation
US$1,151,381
Compensation

Dr. Malte Peters, MD., is Director at HOOKIPA Pharma Inc. since 2023 and is its Chief Executive Officer since July 22, 2024 and served as its Ad Interim Senior Clinical Advisor from September 2023 until Ma...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Barbara Weber
Founder & Executive Chairman of the Board9.3yrsUS$2.82m1.07%
$ 46.2m
Malte Peters
Presidentless than a yearUS$1.15m0.0078%
$ 335.6k
Daniella Beckman
Executive Officerless than a yearUS$1.16m0.091%
$ 3.9m
Adam Crystal
President of Research & Development3.3yrsUS$1.72m0.012%
$ 513.7k
Alan Ashworth
Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
William Kaelin
Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Antoni Ribas
Founder & Member of Scientific Advisory Boardno datapas de donnéespas de données
Matthew Gall
Chief Financial Officerless than a yearpas de donnéespas de données
Jannik Andersen
Chief Scientific Officer2.7yrspas de donnéespas de données
Julie Fogarty
Vice President of Legal & Corporate Secretaryno datapas de donnéespas de données
Julie Carretero
Chief Human Resources Officer2.3yrspas de donnéespas de données
Philippe Serrano
Chief Regulatory Officerless than a yearpas de donnéespas de données
0.4yrs
Durée moyenne de l'emploi
59yo
Âge moyen

Gestion expérimentée: L'équipe de direction de TNGX n'est pas considérée comme expérimentée (ancienneté moyenne 0.4 ans), ce qui suggère une nouvelle équipe.

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Barbara Weber
Founder & Executive Chairman of the Board9.3yrsUS$2.82m1.07%
$ 46.2m
Malte Peters
President7.8yrsUS$1.15m0.0078%
$ 335.6k
Alan Ashworth
Founder & Member of Scientific Advisory Board5.4yrspas de donnéespas de données
William Kaelin
Founder & Member of Scientific Advisory Board5.4yrspas de donnéespas de données
Antoni Ribas
Founder & Member of Scientific Advisory Board5.4yrspas de donnéespas de données
Mace Rothenberg
Independent Director5.3yrsUS$169.70k0.026%
$ 1.1m
Lesley Calhoun
Independent Director5.3yrsUS$176.33k0.0086%
$ 372.7k
John Ketchum
Independent Director2.8yrsUS$196.14k0.012%
$ 524.9k
Sung Lee
Lead Independent Directorless than a yearpas de données0%
$ 0
Alan Huang
Member of Scientific Advisory Board1.4yrsUS$1.88mpas de données
5.3yrs
Durée moyenne de l'emploi
64.5yo
Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TNGX sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/12 07:38
Cours de l'action en fin de journée2026/06/12 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Tango Therapeutics, Inc. est couverte par 14 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Yuan ZhiB. Riley Securities, Inc.
John NewmanCanaccord Genuity
Eric SchmidtCantor Fitzgerald & Co.